申请人:MEDIVIR AB
公开号:WO2010034788A1
公开(公告)日:2010-04-01
Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo; R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem subsituted with fluoro; R4 is methyl or fluoro; m is 0, 1 or 2; E is a bond, or thiazolyl, optionally substituted with methyl or fluoro; A1 is CH or N, A2 is CR6R7 or NR6, provided at least one Of A1 and A2 comprises N; R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O-C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4 alkoxy or F; R7 is H, C1-C4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.
公式II的化合物:其中R1和R2分别为H、F或CH3;或者R1形成乙炔键,R2为H或C3-C6环烷基,可选地被一个或两个从甲基、CF3、OMe或卤素中独立选择的取代基取代;R3为C1-C3烷基或C3-C6环烷基,两者可选地被一个或两个甲基和/或氟、三氟甲基或甲氧基取代,当R3为C3-C6环烷基时,它也可以选择地被氟原子取代;R4为甲基或氟;m为0、1或2;E为键,或噻唑基,可选地被甲基或氟取代;A1为CH或N,A2为CR6R7或NR6,至少其中一个为N;R6为H、C1-C4烷基、C1-C4卤代烷基、C1-C3烷氧基-C1-C3烷基,或当A2为C时,R6也可以是C1-C4烷氧基或F;R7为H、C1-C4烷基或F或其药学上可接受的盐、N-氧化物或水合物,在治疗由于cathepsin K的不恰当表达或活化而表征的疾病方面具有用途,例如骨质疏松症、骨关节炎、类风湿关节炎或骨转移。